Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma.

By B. Baysal, R. Ferrell, J. E. Willett-Brozick, E. Lawrence, D. Myssiorek, A. Bosch, A. Mey, Peter E. M. Taschner, W. Rubinstein, E. Myers and 4 more. Science, 2000

1,720 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/333360f37d318ad00081ce502f12822a0a31f3fd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Surgery

Citations in the corpus

A Mitochondrial Paradigm of Metabolic and Degenerative Diseases, Aging, and Cancer: A Dawn for Evolutionary Medicine (2005, background): “SDHD (cytb membrane subunit) (15), SDHC (coenzyme Q-binding membrane subunit)”
Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer (2006, background): “In 2000, Baysal et al. (2000) discovered that the gene mutated in a particular HPGL syndrome associated with the 11q23 locus (PGL1) is in fact SDHD Oncogene (Baysal et al., 2000).”
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. (2008, background): “Familial paraganglioma can be caused by mutations in SDHB , SDHC , or SDHD , three of the four SDH sub-units (Astuti et al., 2001; Baysal et al., 2000; Niemann and Muller, 2000).”
Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. (2011, background): “Similarly, mutations in the TCA cycle enzyme fumarate hydratase occur in a familial form of leiomyomatosis and renal cell cancer [13,22,23].”
The genetic basis of kidney cancer: a metabolic disease (2010, background): “(76;77) Individuals with these hereditary conditions are at risk for the development of extraadrenal paraganglioma or pheochromocytoma and carotid body tumors.”
Targeting Metabolism for Cancer Therapy (2017, background): “Affected families inherit one defective copy of either FH or SDH, and develop an aggressive form of cancer upon loss of heterozygosity (Baysal et al., 2000; Tomlinson et al., 2002).”
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. (2005, background): “Inherited neoplastic syndromes are also associated with mutation of the succinate dehydrogenase (SDH) complex (Astuti et al., 2001; Baysal et al., 2000; Niemann and Muller, 2000), which catalyzes the conversion of succinate to fumarate in the TCA cycle.”
Progress in understanding molecular mechanisms and evolution of resistance to succinate dehydrogenase inhibiting (SDHI) fungicides in phytopathogenic fungi (2010, result): “This latter result is in accordance with other studies demonstrating that mutations in SDH genes affecting the QP site in mutants of different organisms correlated with a hypersensitivity to oxidative stress (Baysal et al., 2000; Ishii et al., 1990, 1998; Szeto et al., 2007).”
Mitochondrial mutations in cancer (2006, background): “…dehydrogenase B then transfers the electrons to the cytochrome b (cytb) and ubiquinone associated components SDH C and SDH D. Mutations in SDH B (Astuti et al., 2001; Vanharanta et al., 2004), SDH C (Baysal et al., 2000), and SDH D (Niemann and Muller, 2000) all cause the cancer paraganglioma.”
Metabolic reprogramming and epigenetic modifications on the path to cancer (2021, background): “Fumarate and succinate antagonize the roles of α-KG In addition to IDH1 and IDH2, germinal and somatic mutations of fumarate hydratase (FH) and succinate dehydrogenases (SDHA, SDHB, SDHC, SDHD, and SDHAF2), encoding FH and SDH enzymes, are common in a number of human cancers (Baysal et al., 2000; As”